Abstract
The most prevalent types of human papillomavirus in cervical cancer in India are HPV 16 and HPV 18, found in 60.7 per cent and 16 per cent of cases respectively. A comprehensive strategy with a judicious mix of interventions on health promotion, specific protection (vaccination), early diagnosis (screening), and treatment should be instituted to prevent and control cervical cancer in India. Proponents of vaccination and screening argue for enhanced investments on these interventions based on their relative cost-effectiveness. For policymakers, the major concerns about these interventions remain affordability and cost to government. Herein we try to review comprehensively the evidence on prevention and control interventions and to recommend appropriate policies to guide public health decision-making.
This is a preview of subscription content, log in via an institution to check access.
References
Ferlay, J., Shin, H.R., Bray, F., Forman, D., Mathers, C. and Parkin, D.M. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer 127 (12): 2893–2917.
WHO/ICO Information Centre on HPV and Cervical Cancer. (2007) HPV and cervical cancer in the 2007 report. Vaccine 25 (3): C1–230.
Walboomers, J.M. et al (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. Journal of Pathology 189 (1): 12–19.
Smith, J.S. et al (2007) Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update. International Journal of Cancer 121 (3): 621–632.
Sankaranarayanan, R. et al (2008) Human papillomavirus infection and cervical cancer prevention in India, Bangladesh, Sri Lanka and Nepal. Vaccine 26 (12): M43–M52.
Sundström, K. et al (2010) Prospective study of human papillomavirus (HPV) types, HPV persistence, and risk of squamous cell carcinoma of the cervix. Cancer Epidemiology, Biomarkers & Prevention 19 (10): 2469–2478.
Vaccarella, S. et al (2006) Reproductive factors, oral contraceptive use, and human papillomavirus infection: Pooled analysis of the IARC HPV prevalence surveys. Cancer Epidemiology, Biomarkers & Prevention 15 (11): 2148–2153.
Shepherd, J., Peersman, G., Weston, R. and Napuli, I. (2000) Cervical cancer and sexual lifestyle: A systematic review of health education interventions targeted at women. Health Education Research 15 (6): 681–694.
Harper, D.M. et al (2004) Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomised controlled trial. Lancet 364 (9447): 1757–1765.
Muñoz, N. et al (2009) Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: A randomised, double-blind trial. Lancet 373 (9679): 1949–1957.
Lu, B, Kumar, A., Castellsagué, X. and Giuliano, A.R. (2011) Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: A systematic review & meta-analysis. BMC Infectious Diseases 11: 13.
FUTURE II Study Group. (2007) Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. New England Journal of Medicine 356 (19): 1915–1927.
Haug, C.J. (2008) Human papillomavirus vaccination – Reasons for caution. New England Journal of Medicine 359 (8): 861–862.
Bosch, F.X., Castellsagué, X. and de Sanjosé, S. (2008) HPV and cervical cancer: Screening or vaccination? British Journal of Cancer 98 (1): 15–21.
Arbyn, M. et al (2008) Pooled analysis of the accuracy of five cervical cancer screening tests assessed in eleven studies in Africa and India. International Journal of Cancer 123 (1): 153–160.
Franco, E.L. and Harper, D.M. (2005) Vaccination against human papillomavirus infection: A new paradigm in cervical cancer control. Vaccine 23 (17–18): 2388–2394.
Schiffman, M., Castle, P.E., Jeronimo, J., Rodriguez, A.C. and Wacholder, S. (2007) Human papillomavirus and cervical cancer. Lancet 370 (9590): 890–907.
Hill, A.B (1965) The environment and disease: Association or causation? Proceedings of the Royal Society of Medicine 58 (5): 295–300.
Saxenian, H. and Hecht, R. HPV vaccines: Costs and financing. Background paper prepared International AIDS Vaccine Initiative (IAVI)for Stop Cervical Cancer: Accelerating Global Access to HPV vaccines; 12–13 December, London, UK.
Diaz, M. et al (2008) Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India. British Journal of Cancer 99 (2): 230–238.
Task Force Reports for XIth plan. (2005) National Cancer Control Programme. Cancer Prevention and Control. Task Force Reports for XIth plan, http://www.whoindia.org/LinkFiles/Cancer_resource_nccpXI_cancer_prevention.pdf, accessed 8 October 2011.
Gakidou, E., Nordhagen, S. and Obermeyer, Z. (2008) Coverage of cervical cancer screening in 57 countries: Low average levels and large inequalities. PLoS Medicine 5 (6): e132.
Legood, R. et al (2005) Screening for cervical cancer in India: How much will it cost? A trial based analysis of the cost per case detected. International Journal of Cancer 117 (6): 981–987.
Author information
Authors and Affiliations
Additional information
The authors assess the role of various elements in a comprehensive control program based on India's experience.
Rights and permissions
About this article
Cite this article
Farooqui, H., Zodpey, S. Cervical cancer control in India: Taking evidence to action. J Public Health Pol 33, 165–172 (2012). https://doi.org/10.1057/jphp.2012.7
Published:
Issue Date:
DOI: https://doi.org/10.1057/jphp.2012.7